1	Genotypic Characterization of Urinary Tract Infections causing bacteria isolates among Adults at
2	Kiambu Level 5 Hospital, Kenya: Selected Extended Spectrum <i>β</i> -Lactamase genes and Biofilm
3	Formation
4	Fredrick Kimunya Wanja ^{1*} , Eric Omori Omwenga ² , Caroline Wangare Ngugi ¹ , John Ndemi Maina ³ ,
5	John Ndemi Kiiru ³
6	¹ Department of Medical Microbiology, Jomo Kenyatta University of Agriculture and Technology, P.O. Box 6200-00200 Nairobi, Kenya.
7	² Department of Medical Microbiology & Parasitology, Kisii University, P.O. Box 408-40202, Kisii, Kenya.
8	³ Centre of Microbiology Research, Kenya medical Research Institute, P.O. Box 43640-00100 Nairobi, Kenya.
9	
10	*Corresponding author email: - <i>wanjakimunya@gmail.com</i> ; Mobile number: <u>+254 724 089245</u>
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 Abstract

The menace of antimicrobial resistance to public health is constantly arising globally. Many pathogenic 23 bacteria use mechanisms such as mutations and biofilm formation, which significantly reduces efficacy of 24 antimicrobial agents. In this cross-sectional study, we aimed at determining the prevalence of selected 25 extended spectrum β -lactamase (ES β Ls) genes and analyse the possible biofilm formation abilities of the 26 isolated bacteria causing urinary tract infection among adult patients seeking medicare at Kiambu Level 5 27 hospital, Kenya. The double-disk synergy test was used for phenotypic identification of ESBLs producing 28 isolates, while microtiter plate assays with some modifications were used to test biofilm formation analysis. A 29 total of 10 isolates were bioassayed for ESBL genes presence out of 57 bacteria isolates obtained from urine 30 samples. From this study, the *bla_{TEM}* genes were found to be the most prevalent ESBLs genes (100%), 31 followed by *blaoxA* and *blasHV* genes at 40% and 30% respectively. In addition, the co-carriage of *blaTEM* and 32 bla_{SHV} was revealed at 50% lower than that of $bla_{TEM} + bla_{OXA}$ genes at 66.7% among the study E. coli 33 isolates. Biofilm formation finding disclosed that most of the isolates form biofilms 36 (63.2%), with Gram-34 negatives being the most biofilm formers 25 (69.4%) compared to the Gram-positive 11 (30.6%). E. coli 35 15(41.7 %), *Klebsiella sp.* 7(19.4%) and *S. aureus* 7(19.4%) were the most common biofilm formers. Further 36 analysis showed no significant difference in biofilm formation among all tested isolates with a p-value of 37 more than 0.05. However, overall Gram-positive isolates had a significant P-value of 0.056. Although biofilm 38 formation's impact on urinary tract infections is not fully recognized, the carriage of ESBLs resistance genes 39 40 and the biofilm formation ability negatively impact effectiveness of UTI treatment. Therefore, we advocate for surveillance studies to map ESBLs distribution and biofilm formation genes among UTI etiological agents 41 to halt UTI treatment failure. 42

43 Keywords: Antimicrobial resistance (AMR), Resistance genes, Biofilm formation, Antibiofilm inhibitory
44 effects, Extended Spectrum β- Lactamase (ESβLs)

46 **1.0 Introduction**

Bacterial UTIs continue to be a major public health concern that affects both the genders and age groups 47 48 globally (1). These infections can easily be treated with existing antimicrobials, but treatment options are becoming fewer with the ever-increasing, (re)-emergence and spread of antimicrobial resistance (AMR) (2). 49 The situation has been made worse with the emergence of multi drug and extra drug resistant strains with 50 projections of reaching soon an antibiotic free world in the horizon (1). This has been attributed to the lack of or 51 poor regulation implementation and widespread use/misuse of antibiotics globally; hence the resistance patterns 52 of bacteria causing UTIs are changing drastically. This has been worsened by the emergence and spread of 53 AMR, which has become more rampant in developing countries, Kenva included, with minimal strategies being 54 employed to curb this menace (2). The change in AMR patterns has been attributed to various strategies being 55 employed by bacteria, like the hydrolyzing activities of extended-spectrum β -lactamase (ES β L) and biofilm 56 formation abilities of the UTIs causing pathogen which ends up shielding the bacteria from potent antimicrobial 57 agents amongst many (3). For instance, the carriage of ESBLs genes by bacteria causing UTIs has been cited for 58 mediating resistance to extended spectrum Cephalosporins (3). This is despite the fact that most β -lactam 59 antibiotics have been reported to be potent against both Gram-positive and Gram-negative bacteria. The recent 60 noted resistance cases against this class of antibiotics are actually of immense clinical significance (4). With 61 this knowledge and many more, there is a pressing need to build up amicable antimicrobial stewardship to 62 better our understanding of the changing antibiotic resistance trends. 63

Various studies done at the global level have documented enormous and ever-increasing distribution levels of ES β L producing bacteria, a trend that should be of great concern globally (5). For example, a study done in Iran indicated the mass prevalence of the presence of β -lactamase genes (96.3%) amongst the study isolates (6). Almost similar results were documented in a recent study conducted in the Philippines, where the prevalence and distribution of ES β Ls-encoding genes was 66.6% (5). This could be attributed to the fact that ES β Ls are mostly located on plasmids and transposons, which easily facilitates the transmission dynamics of these

resistance traits amongst pathogens within and between species presenting an infection control risk, particularly
within hospitals (7).

However, regionally, and particularly in Kenya, the knowledge of carriage of EβSLs among urinary tract infection etiological agents is still a normal challenge beyond most clinicians reach (4). In addition, the limited knowledge and the rising AMR among bacterial agents causing UTIs due to the carriage of EβSLs can be associated with the poor epidemiological surveys, phenotypic and genotypic characterization of multi-drug resistance micro-organisms in developing countries. As a result, UTIs caused by pathogens possessing EβSLs genes have proved difficult to treat due to limited antibiotic treatment options that are not readily available in these poor resource-limited settings (7).

Biofilms are exopolysaccharide polymers formed on a mass of bacterial cells that then houses them as they 79 keep on multiplying and producing more virulence traits (8). Even though pathogenic and non-pathogenic 80 81 bacteria can form biofilms, some of the most common bacteria causing UTIs have been identified to be good biofilm formers (8). Among the most common UTI causing bacterial isolates includes; E. coli, S. aureus and 82 P. aeruginosa, even though E. coli has been singled out as the most notorious biofilm former (8). According 83 to a prior study, bacteria that exist in biofilms exhibit extraordinary resistance to conventional biocides, 84 antimicrobial treatments and host immune response compared to their planktonic (non-adherent) counterparts 85 (9). Once micro-organisms form biofilms, they alter their phenotypic characteristics, reducing their 86 susceptibility to antibiotics (10). This influences microbial responses to stimuli in medical and non-medical 87 settings, especially the responses towards antimicrobial agents and the host immune system. The observed 88 phenotypic changes are associated with the microbe genetic diversity since the expression of genes within the 89 said community leads to biofilm formation (11). To succeed in UTI treatment and halt recurrency, more 90 research on biofilm formation and the impact association to resistance of UTI causative agents to commonly 91 used antibiotics will help tailor prudent treatment solutions. 92

This ability to form biofilms by most UTI etiological agents, the contribution of the biofilms to uropathogens 93 resistance to antibiotics needs to be well understood. Furthermore, our understanding of the interplay between 94 biofilm and AMR among bacteria causing urinary tract infections worldwide and how to best treat these 95 infections is limited (10). Again, the distribution of biofilm formation genes among bacteria causing UTIs is 96 under-investigated. However, microbes that live closely in biofilms are said to embrace cellular signaling 97 communication mechanisms to ensure all collaboration for optimum benefits. Future studies on the 98 association between biofilm formation and AMR should be seen as a greater way of understanding biofilm 99 processes, leading to novel, effective antibiofilm inhibitory strategies and improving patient management (11). 100 The clinical effect of these biofilms and how they afford pathogens a favorable environment to thrive should 101 be seen a scientific gap that needs to be elucidated. These biofilms also give pathogens more time to escape 102 the cidal/ static activities of antimicrobials (12)(13), meaning more genetic and molecular advances will also 103 better our understanding of these bacterial communities, boosting treatment. 104

To assist halt biofilm establishment and dissolution of the already existing ones, long-term solutions with 105 significant antibiofilm inhibitory effects are paramount (14). More so, because the interplay between antibiotic 106 resistance and biofilm formation remains unclear and has a significant impact on the cost of medical treatment 107 and prevention of infectious diseases (15)(16). The use of drugs with antibiofilm inhibitory effects will 108 therefore aid in unmasking the biofilm exopolysaccharide matrix allowing efficient penetration of antibiotics 109 and host immune responses into biofilms, which will result in minimum resistance and hampering of 110 antibiotic therapy (17). This current study finding therefore sheds light on the prevalence of E β SLs and 111 possible abilities to biofilm formation among bacterial isolates causing UTI among adult patients seeking 112 medicare at Kiambu Level 5 hospital, Kenya. The revealed finding also equips health caregivers with crucial 113 information that will diagnose and probable potential treatment solutions for urinary tract infections. 114

115

117 Materials and Methods

118 **2.1 Study design, site and ethical approval**

This cross-sectional study was done in Kiambu level 5 Hospital, Kiambu County – Kenya (1°10′S36°50′E).
The study's ethical approval was sought from the Kenyatta National Hospital-University of Nairobi Ethical
Research Committee (Reference no: KNH-ERC/A/470) and National Commission for Science, Technology,
and Innovation (NACOSTI) (Reference no: 619853).

123 2.1.1 Ethics Statement

The principal investigator was at the laboratory reception all the time and explained the goal of the study to each adult patient into details to ensure smooth recruitment exercise. After the detailed explanation, consent of the participant was sought, which required him/her to fill in and sign the consent form (Supplementary data S1).

128

129 2.2 Sample size

This present study involved isolates from our previous study by Wanja *et al.* (18)where 57 significant bacterial isolates and 31 non-significant growths below the $\geq 100,000$ CFU/ml (10⁵) threshold were obtained. Therefore, the 57 UTI-positive isolates were used as our sample size to determine the possibility of biofilm formation. On the other hand, isolates resistant to 3rd generation cephalosporins (Ceftriaxone, Cefotaxime and/or Ceftazidime) and ampicillin were screened for the E β SLs genes carriage (18).

135 **2.3. Molecular detection of EβSLs**

136 *i. Phenotypic detection of EβSLs*

A double-disk synergy test to detect the likelihood of isolates carriage of E β SLs was performed using disks of 3rd generation Cephalosporins and Cephalosporin-inhibitor (Clavulanic acid) antimicrobial disk as previously described (19) (20). The test disks of 3rd generation Cephalosporins and Ceftazidime/Clavulanic acid were used. On inoculated Mueller-Hinton agar, the disks were kept 30mm apart, centre to centre. A clear extension of the edge of the inhibition zone of Cephalosporin towards the Augmentin disk was observed was interpreted as a positive for E β SL production as done before (18). All tests were independent of each other.

143

144 *ii. DNA extraction*

The DNA template for the PCR test was obtained using the boiling method as previously described (21). Briefly, a loopful of pure bacterial inoculum was immersed into 1mL of PCR grade water (Invitrogen, DNase/RNase free) in a 2mL Eppendorf tube. Lysis of the bacterial cell membrane was done by boiling at 95°C for 15 minutes in a thermal block (Twin incubator, DG 210). The separation of DNA from other cell extracts was done by centrifuging (BioSan LMC- 3000 Centrifuge; Serial no; 90804012, CHINA) at 1400 rpm for 5 minutes. The supernatant containing extracted DNA was transferred to another Eppendorf tube and stored at -20°C (21).

152 *iii. Genotypic Identification of EβSLs Genes*

Molecular screening was done by PCR method to determine the carriage of selected E β SLs genes (*bla*CTX-M, *bla*SHV, *bla*TEM and *bla*OXA) as described by previous studies (22) (23) (24). The final volume in each PCR tube was 25µl which included 10 µl of Qiagen master mix, 1 µl butane, 2 µl DNA, 10 µl PCR water, and 2 µl forwards and reverse primer (specific to each target gene). Amplification was done using a thermal cycler (GeneAmp® PCR system 9700) under the following conditions; initial denaturation at 95 °C for 2 min, annealing at 50 - 60 °C (depending on the primer) for 1 min, extension at 65 °C for 8 min and a single final

- 159 extension step at 65 °C for 8 min for 30 cycles. Amplified PCR products were separated in 1.5% gel and
- 160 banding patterns were visualized under a UV gel imager.
- 161 **Table 2.1:** PCR Amplification primers used

PCR Amplification primers used					
AMR	Primer	Primer sequence	Annealing	Product	Reference
gene	name		T(°C)	size	
bla _{тем}	TEM-F	5'-ATGAGTATTCAACATTTC CG-3'	50	867 bp	(22)
	TEM-R	5'-CCAATGCTTAATCAGTGA CG-3'			
bla shv	SHV-F	5'-TTCGCCTGTGTATTATCTCCCTG-3'	50	854 bp	(23)
	SHV-R	5'-TTAGCGTTGCCAGTGYTCG-3'			
bla oxa	OXA-F	5'-ATGAAAAACACAATACATATCAACTTCGC-3'	62	280 bp	(24)
	OXA-R	5'-GTGTGTTTAGAATGGTGATCGCAT T-3'			
bla стх- м	CTX-M-F	5'-ATGTGCAGYAACAGTAARRGTKATGGC-3'	60	593 bp	(23)
	CTX-M-R	5'-TGGGTRAARTARGTSAACAGAAYCAGCGG-3'			

162 **Keyword:** *bla-* β *lactamase genes*; **bp-** molecular weight in base pairs

163 iv. Genetic analysis of E. coli Isolates

Resistance to either of the tested expanded spectrum cephalosporin was used as a basis for selection of six E. 164 coli isolates for repetitive tandem repeats analysis. This analysis was done using the GTG 5-PCR method 165 using published strategies and primers indicated in Table 2.1. PCR amplification of the target DNA sequence 166 was done at an initial step of denaturing for about 1 minutes at 95°c, then the second fold of annealing at 40°C 167 temperature and finally the third fold of the final extension at 72°c. Amplified products were separated by 168 running in 1% agarose gel for I hour. Visualization of banding patterns was done using a Gelmax® UV 169 imager. Banding patterns were analyzed using bionumerics Gelcompar®2 software versions 6.6, with the 170 cluster analysis done using the dice method based on UPGMA arithmetic mean. As previously described, a 171

172	correlation of \geq 80% among bacterial species was regarded as strong evidence of genetic relatedness among
173	isolates (25).
174	
175	
176	
177	
178	
179	2.4. Biofilm formation Assay

The study test isolates' ability to form biofilm was determined using 96 well microtiter plate assays with some 180 modifications as described before (26). The isolates stored at -80°C in vials were first thawed, 10 µl picked 181 and inoculated into 190µl Tryptone Soya Broth (TSB-OXOID, UK) and incubated in a microtiter plate for 48 182 hours at 37°C without shaking. By use of a parafilm, the flat-bottomed 96 well microtiter plates were sealed 183 for purposes of preventing medium evaporation. After the incubation, the microtiter plates were rinsed gently 184 2-3 times with double-distilled water 200ul to remove loosely attached cells/planktonic cells. The microtiter 185 plate was then air-dried for 1 hour before adding 200 µl per well of 0.4% crystal violet solution to the adhered 186 cells in the microtiter plates and left at room temperature for 15min. Excess stain was removed by rinsing the 187 microtiter plates gently with 200µl of distilled water per well three times. These microtiter plates were then 188 air-dried again for 1 hour and then 200µl of absolute ethanol was added to solubilize the dye. The intensity 189 was measured at optical density (OD₆₃₀nm) using a Safire Tecan-F129013 Micro Plate Reader (Tecan, 190 Crailsheim, Germany). Background staining of each experiment was corrected by subtracting the crystal violet 191 bound to un-inoculated controls from those of the samples using the formula by Omwenga et al (27). 192 Antibiofilm formation inhibitory activity was carried out using the selected eight bacteria isolates (E.coli 193

3323, E.coli 5810, Klebsiella spp 3306, Klebsiella spp 3063, Staphylococcus spp 3309, Staphylococcus spp 194 3328, Proteus spp 3346, and Proteus spp 3268) that were obtained from our previous study (18). The 195 treatment drugs used for the antibiofilm formation inhibitory activity assay were in different 196 dosages/concentrations as follows; Ampicillin (AMP)-500mg/ml, 250mg/ml, 125mg/ml and 62.5mg/ml: 197 Ciprofloxacin (CIP)-500mg/ml, 250mg/ml, 125mg/ml and 62.5mg/ml: Sulfamethoxazole (SXT) -960mg/ml, 198 480mg/ml, 240mg/ml and 120mg/ml: Ceftriaxone (CRO)-1000mg/ml.500mg/ml.250mg/ml and 125mg/ml. 199 To estimate the antibiofilm activity (Abf A) of a given antibiotic, the following equation was used (27). 200 Antibiofilm formation ability (Abf A) (%) = $(1-(ODTest \ sample - ODBlank)/(OD \ Untreated \ sample - OD$ 201 Blank) $\times 100$. 202

All these tests were carried out in triplicates independent of each other and *Pseudomonas aeruginosa* (ATCC27853) was used as the study reference strain.

205 2.5. Data Analysis

The study findings were later entered into excels spread sheets for analysis using graph pad prism version. ANOVA Dunnett's multiple comparisons test was applied to determine the antibiofilm formation inhibitory assays. Binary logistic regression analysis was carried out to generate the adjusted odds ratio with a 95% confidence interval. An alpha of less than 0.05 (P<0.05) was considered statistically significant. medRxiv preprint doi: https://doi.org/10.1101/2022.10.23.22281223; this version posted October 25, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

3.0 Results 210

211 3.1 Study population and sample size

From the outpatient department, 174 (84.5%) were recruited, while inpatient 32 (15.5%) were from the 212 inpatients [18]. The overall age mean among study participants was 31.8 years. Out of the two hundred and 213 six (206) midstream urine samples collected from the participants, only 57 had significant urinary tract 214 infection growth, which translates to a prevalence of 27.6%. Therefore, the 57 significant isolates were used 215 as the sample size of this current study and were subjected to EßSL and biofilm formation analysis (18). 216

3.2.1 Prevalence of β-lactamase Phenotypes 217

From the 57 isolates that met the threshold for significant UTI, 14 (24.6%) were resistant to Ceftriaxone, 218

Cefotaxime or Ceftazidime and were regarded as possible ESBL producers. However, only 10 (17.5%) were 219

confirmed as ESBL producers by the double disk method (4). 220

Further screening for genotypic carriage of selected *bla* genes showed that TEM was present in all the 10 221

(100%) screened isolates revealing readings more than 867 bp, as demonstrated in figure 3.2-C and Table 222

3.1 below. In addition, Figure 3.2-A demonstrates that EBSLs blaoxA genes were detected 30% findings 223

more than 854 bp among *E. coli* isolates while in Figure 3.2-B the prevalence of EßSLs genotype *blashy* is 224

demonstrated at 40% with findings more than 280 bp among E. coli isolates. 225

Analysis based on the co-carriage of E β SLs genes revealed the co-carriage of *blatem* and *blaoxa* among *E*. 226

coli isolates at 66.7% and the co-carriage of *blaTEM* + *blaSHV* at (50%) as demonstrated on **Table 3.1** below. 227





Figure 3.2: Electrophoresis gel results for *bla_{SHV}* genes (A), *bla_{OXA}* genes (B) and *bla_{TEM}* genes (C).



Figure 3.1: EβSLs genes results of the obtained bacterial isolates

232 Key word: *bla-* β *lactamase genes*; % - percentage

EβSL genes co-carriage (n)					
Organism	N	bla TEM+bla SHV+bla OXA	bla TEM+bla OXA	bla _{TEM+} bla _S	HV
E. coli 6		3(6)	4(6)	3(6)
Klebsiella species	2	0(2)	0(2)	0(2)
Proteus species	2	0(2)	0(2)	0(2)
All	10	3	4		3
Organism	Biofilm former	Non-biofilm formers	OR	95% CI	P-value
E. coli	15	9	1.03	0.384-2.758	0.9554
Klebsiella species	7	3	0.74	0.171-3.15	0.6781
Proteus species	3	3	1.71	0.317-9.276	0.5315
S. aureus	7	4	0.98	0.256-3.746	0.976
Enterococcus species	0	1	5.09	0.199-130.659	0.3254
S. saprophyticus	4	1	0.43	0.045-4.093	0.4617
Gram- negative	25	15	1.03	0.446-2.374	0.9474
Gram-positive	11	6	2.49	0.976-6.368	0.0561*
Department	Biofilm former-36(63.2%)	Non-biofilm former-21(36.8%)	Total (%)		
Out patient	32	17	49(85.9%)		

In patient	4	4	8(14 %)	
Odds ratio	· · · ·	· · ·	1.860542	·
P-value			0.4053425	
95% CI	0.3057786	11.36315		
Gender	Biofilm former (%)	Non-biofilm former (%)	Total (%)	
Men	2(5.6%)	1(4.7%)	3(5.3%)	
Female	34(94.4%)	20(95.2%)	54(94.7)	
Female odds ratio	34(94.4%)	20(95.2%)	54(94.7)	

Keyword: *bla-* β *lactamase genes*; % - percentage; N–number of cases

3.3 Genetic diversity of E. coli isolates causing UTIs

The six isolates: Ec1- *E.coli* 5806; Ec2- *E.coli* 3352; Ec3- *E.coli* 3323; Ec4- *E.coli* 3177; Ec5- *E.coli* 3318
and Ec6- *E.coli* 3350 did not cluster based on similarities in antimicrobial resistance profiles or β-lactamases
genes carriage. For instance, Isolates *E.coli* 5806 and *E.coli* 3350 had identical resistance profiles (AMP,
CRO, CAZ, CTX) yet clustered in different clades. This was also similar to isolates *E.coli* 3352 and *E.coli* 3323 that also had identical antimicrobial resistance (AMP, ATM, CRO, CAZ, CTX) and clustered into two
different clades. Therefore, the six isolates could be grouped into four clades with similarities of between 65

243 – 86%, which could reflect no indication of similar strain expansion in the Kiambu region, Figure 3.3.



236





250 Figure 3.3: Escherichia coli dendrogram

Key: The figure shows phylogeny analysis of *Escherichia coli* isolates that were positive for the carriage of
EβSLs genes. Description of various acronyms on this figure is as follows; *E. coli*: *Escherichia coli*, AMR:
Antimicrobial resistance, *bla*_{TEM}: Temoneria β-lactamase, *bla*_{CTX-M}: Cefotaxime Munich β-lactamase, *bla*_{SHV}: Sulhydryl variant β-lactamase, *bla*_{OXA}-type β-lactamases

255

3.4.1 UTIs isolate Biofilm formation assay 257

The biofilm formation assays revealed that majority of the screened study isolates were biofilm formers -258 63.2% (36/57) to non- biofilm formers at 36.8% (21/57). Gram-negative isolates had the highest biofilm 259 formation prevalence at 69.5% (25/36) compared to the Gram-positive 30.5% (11/36). With E. coli 260 15(41.6%), Klebsiella sp. 7 (19.5%) and S. aureus 7 (19.5%) respectively being the most common biofilm 261 formers as demonstrated in Table 3.1 above. 262

Further analysis based on significance of the results, showed no significant difference in biofilm formation 263 among the tested isolates with a p-value of more than 0.05 recorded across board. However, analysis based 264 on bacteria classification revealed that Gram positive isolates yielded significant biofilm formation ability 265 with a notable P-value of 0.0561 Table 3.1 above. 266

- From the 57 analysed isolates the outpatient department had 49 (85.9%), a prevalence of 88.9% (32/36) 267
- biofilm formers compared to the inpatient 11.1% (4/36). Non- biofilm formers prevalence findings were also 268
- similar with the outpatient biofilm formation prevalence at 80.9 % (17/21) to 19.1 % (4/21) of the in-patient 269
- department. In addition, biofilm formation was prevalent in women's urine isolates at 62.9 % (34/57) 270
- compared to men's at 5.6 % (2/57) as summarized in Table 3.1 above 271

3.4.2 Antibiofilm formation inhibitory activity assay 272

Antibiofilm formation activity assay was carried out for eight bacteria isolates that were selected based on 273 their antimicrobial resistance activity against test antibiotics in our previous study (18). The revealed data 274 demonstrated that the biofilm formation inhibitory effects varied differently between the study isolates 275 species and the various antibiotic dosages in comparison to the positive control as demonstrated in Figure 276 3.5.1; 3.5.2, 3.5.3 and 3.5.4. Ceftriaxone had the best antibiofilm inhibitory effects at all dosages compared 277 to the rest of the test treatment antibiotics. On the other hand, Sulfamethoxazole yielded the least observed 278 antibiofilm inhibitory effects across the four dosages as demonstrated in figure 3.5.3 below. Further analysis 279 also revealed that Gram-negative isolates had the most antibiofilm inhibitory effects compared to the Gram-280

positive *Staphylococcus species*. In addition, analysis based on how each species were affected show
 Proteus spp were more susceptible to treatment drugs at various dosages compared to the rest of the isolates

283 Figure 3.5.1 to Figure 3.5.4.

284 3.4.2.1: Ampicillin antibiofilm effect/activity

The antibiofilm effects findings against ampicillin revealed huge variation more so amongst isolates of the same species. For instance, among the *E. coli* isolates; *E. coli* 3323 isolate yielded moderate antibiofilm inhibitory effects especially when subjected to ampicillin 500mg/ml and 250mg/ml dosages when compared to that of *E. coli* 5810 isolate against the same 500mg/ml and 250mg/ml dosages **Figure 3.5.1 below.**

In addition, Staphylococcus *spp* 3328 and *Proteus spp* 3268 isolates in the various test drug dosages yielded significant antibiofilm formation inhibition activity (P = *** = 0.001; **** = 0.0001). However, across all the ampicillin dosages, *Klebsiella spp* 3306 yielded the least antibiofilm inhibition effect recording p value of ** = 0.01 against the dosage of 250 mg/ml. The revealed ampicillin antibiofilm inhibition findings are therefore promising and demonstrate that even though most of the isolates were resistant to ampicillin, it's still a good antibiofilm formation drug.

Further analysis based on the ampicillin dosages inhibitory effects also demonstrated huge variations. The low dosages of 62.5 mg/ml and 125 mg/ml had significant differences on the antibiofilm inhibition activity compared to the higher dosages 250 mg/ml and 500mg/ml Figure 3.5.1 below. This observation may be explained by the fact at high concentrations sometimes aggregation of the drug can occur at the point of entry unto the bacteria cell and hence not much of the drug enters the target site.



FIG: 3.5.1 Ampicillin antibiofilm formation activity against (A) *E. coli* 3323 Isolate (B) *E. coli* 5810 Isolate (C)
 Klebsiella spp 3306 Isolate (D) *Klebsiella spp* 3063 Isolate (E) *Staphylococcus spp* 3309 Isolate (F)
 Staphylococcus spp 3328 Isolate (G) *Proteus spp* 3346 Isolate and (H) *Proteus spp* 3268 Isolate; PC=*P*.

aeruginosa – Positive control (*n*=3, ANOVA Dunnett's multiple comparisons test; **P*=0.05; ***P*=0.01; ****P*=0.001;
 *****P*=0.0001).

306 3.4.2.2: Ciprofloxacin antibiofilm effect/activity

300

The antibiofilm inhibitory finding against ciprofloxacin showed majority of the isolates being significantly affected when subjected to the various ciprofloxacin dosages. For instance, *Klebsiella spp* 3063 and *Staphylococcus spp* isolates were greatly affected revealing significant antibiofilm inhibitory effects in presence of the different ciprofloxacin test dosages (p value of **** = 0.0001). However, moderately antibiofilm inhibitory activities were yielded among isolates *E. coli* 3323; *E. coli* 5810 and *Klebsiella spp* 3306 recording p value of ** = 0.01 and *** = 0.001respectively.

- 313 The least affected isolates were the *Proteus spp* isolates with *Proteus spp* 3268 isolate yielding no inhibitory effect
- 314 when subjected to 62.5mg/ml, 125 mg/ml and 250 mg/ml ciprofloxacin dosages as compared to its counterpart
- 315 *Proteus spp* 3346 isolate that was highly affected **Figure 3.5.2 below.**

Further antibiofilm inhibitory findings based on the actual inhibitory impact among the different ciprofloxacin dosages also revealed the 250mg/dl dosage having the highest inhibitory effects. This was closely followed by 62.5mg/ml and 125 mg/ml dosages respectively, while the 500mg/ml dosage had the least inhibitory effects.





FIG: 3.5.2 Ciprofloxacin antibiofilm formation activity against (A) *E. coli* 3323 Isolate (B) *E. coli* 5810 Isolate

- 322 (C) *Klebsiella spp* 3306 Isolate (D) *Klebsiella spp* 3063 Isolate (E) *Staphylococcus spp* 3309 Isolate (F)
- 323 Staphylococcus spp 3328 Isolate (G) Proteus spp 3346 Isolate and (H) Proteus spp 3268 Isolate; PC=P.
- *aeruginosa* Positive control (*n*=3, ANOVA Dunnett's multiple comparisons test; **P*=0.05; ***P*=0.01; ****P*=0.001;
- **325** *****P*=0.0001).
- 326

3.4.2.3: Sulfamethoxazole antibiofilm effect/activity 327

The inhibitory analysis of sulfamethoxazole dosages against the study isolates yielded the least of inhibitory 328 effect overall compared to the rest of the study test drugs as demonstrated in Figure 3.5.3 below. However, 329 sulfamethoxazole inhibitory effect analysis based on how the isolate species were affected revealed the E. 330 coli isolates as the most affected species. E. coli 5810 isolate particularly was the most affected and recorded 331 the highest antibiofilm formation activity especially when subjected to sulfamethoxazole dosages of 240 332 mg/ml, 480 mg/ml and 960 mg/ml; p value of *** = 0.001. In addition, the study Klebsiella 3063 isolate 333 yielded moderate inhibitory effects compared to *Klebsiella spp* 3306 isolate that had no inhibitory effects recorded at 334 all. Moderate inhibitory activity was also revealed by *Proteus spp* 3268 isolates with a p value of * = 0.05335 compared to the other Proteus isolate Proteus spp 3346 that had no inhibitory effects. 336

More analysis based on the various test drugs dosages inhibitory performance also revealed the lower 337 dosages performed better than the higher dosages. However, over all the 240mg/ml dosage performed better 338 than the rest of the Sulfamethoxazole dosages as demonstrated in Figure 3.5.3 below. 339







FIG: 3.5.3 Sulfamethoxazole antibiofilm formation activity against (A) E. coli 3323 Isolate (B) E. coli 5810

342 Isolate (C) *Klebsiella spp* 3306 Isolate (D) *Klebsiella spp* 3063 Isolate (E) *Staphylococcus spp* 3309 Isolate (F)

343 Staphylococcus spp 3328 Isolate (G) Proteus spp 3346 Isolate and (H) Proteus spp 3268 Isolate; PC=P.

344 *aeruginosa* – Positive control (n=3, ANOVA Dunnett's multiple comparisons test; *P=0.05; **P=0.01; ***P=0.001; ****P=0.0001).

346 3.4.2.4: Ceftriaxone antibiofilm effect/activity

Ceftriaxone was the most effective test drug according to our study antibiofilm inhibitory activity analysis. 347 All the ceftriaxone dosages had high or moderate inhibitory effects against all the eight study isolates. 348 However, analysis based on how individual isolate was affected revealed Staphylococcus species were the 349 most affected compared to the rest of the study isolates species. Staphylococcus spp 3328 isolate was the 350 most highly affected yielding an antibiofilm inhibitory activity of a p value of **** = 0.0001 compared to 351 the other Staphylococcus spp 3309 isolate that had been moderately affected. Further analysis based on how 352 also demonstrated that most of the other isolates had moderately antibiofilm formation activity with the only 353 significant variation seen being that of *Klebsiella spp* 3063 that recorded no significant inhibitory effect 354 when subjected to 125mg/ml and 250 mg/ml dosages. 355

In concurrence to the rest of the study test drugs, ceftriaxone dosages also had minimum inhibitory effect yielded by the very high test dosages of 500mg/ml and 1000mg/ml dosages at p values of ** = 0.01 and p value of *P=0.05 respectively compared to the lower dosages of 125mg/ml and 250 mg/ml **Figure 3.5.4 below.**



FIG: 3.5.4 Ceftriaxone antibiofilm formation activity against (A) *E. coli* 3323 Isolate (B) *E. coli* 5810 Isolate (C) *Klebsiella spp* 3306 Isolate (D) *Klebsiella spp* 3063 Isolate (E) *Staphylococcus spp* 3309 Isolate (F) *Staphylococcus spp* 3328 Isolate (G) *Proteus spp* 3346 Isolate and (H) *Proteus spp* 3268 Isolate; PC=*P. aeruginosa* – Positive control (*n*=3, ANOVA Dunnett's multiple comparisons test; **P*=0.05; ***P*=0.01; ****P*=0.001;
*****P*=0.0001).

perpetuity. It is made available under a CC-BY 4.0 International license .

372 **4.0 Discussion**

Bacterial biofilms and carriage of resistance genes may be the basis of most established and persistent 373 urinary tract infections cases. Though scientific research has indicated that there is an ever-increasing 374 antimicrobial resistance and biofilm formation in most infectious diseases causing pathogens including the 375 urinary tract infection causative agents, more studies are needed to tackle this public health issue. Findings 376 from the present study demonstrated the landscape of the interplay between biofilm formation and 377 antimicrobial resistance among the study's isolates. Considering the high UTI prevalence rate of 27.6% and 378 the phenotypic resistance profiles to commonly used antibiotics reported in our previous study (18). It is 379 plausible that the carriage of E β SLs genes may be the major driving factor that influenced resistance of the 380 study isolates against the test antibiotics. The carriage of *bla_{TEM}* was the most prevalent, detected at 100% 381 (10/10) closely followed by *blaoxA* genes at 40% (4/10) and *blasHV* at 30% (3/10) respectively. This signals 382 a clear indication that *blaTEM* genes may have greatly impacted the isolates resistance profiles as this gene is 383 responsible for resistance towards important classes of ß-lactams antibiotics like Cefuroxime, Cefotaxime 384 and Ceftriaxone as reported in previous studies (28)(29). 385

Findings from our previous study on the presence of *blatem* genes seemed to imply that the genes enhanced 386 the ability of obtained bacteria isolates to inactivate ampicillin at a range of 17% to 67%, Cefotaxime at 18% 387 388 to 50 and Ceftriaxone at 18% to 29% (18). Moreover, the carriage of *blatem* genes among *Klebsiella* and *Proteus* species was recorded at 20% respectively; an observation that may be afflicted to the revealed high 389 resistance profiles of Klebsiella and Proteus species against Sulfamethoxazole and Ampicillin at range 390 between 50% - 85% (18). The revealed *blatem* finding therefore concurs with other findings from related 391 studies that documented *bla_{TEM}* genes being responsible for increasing bacteria pathogen's hydrolysing 392 393 activity against penicillin and first-generation Cephalosporin (28)(29).

On the other hand, the carriage of bla_{SHV} and bla_{OXA} genotypes among *E. coli* and *Klebsiella pneumoniae* isolates was also revealed at 40% and 30 % respectively, a confirmation that the distribution of these E β SL genes have spread across most of the commonly known bacteria of medical importance. These two E β SL genotypes have in the recent past been documented to being able to confer drug and multidrug resistance

(29), with the most commonly reported significant resistance being noticed against extended-spectrum 398 cephalosporins, a class of antibiotics that are of immense clinical significance (29). This observation 399 therefore underpins the role of the carriage of bla_{SHV} and bla_{OXA} EBSL genotypes as major contributors of 400 the rising treatment failure. However, going by this study data, more surveillance program to monitor the 401 carriage of new mutant *blashy* and *blaoxA* genes that are emerging is urgent (30). This is so because *blashy* 402 genes are often encoded by self-transmissible plasmids and can easily be transmitted along with other 403 resistance genes leading to significant clinical challenges (4). Furthermore, the current epidemiolgy of 404 *blashy* genes have also shown that their prevalence among members of the Enterobacteriaceae have been on 405 the rise in the last decade, and that the genes have evolved from a narrow to an extended-spectrum of 406 hydrolzing activity.especially against monobactams and carbapenems antibiotic classes (31). 407

In the current study, the carriage of *blaoxA* gene was actually common among the study *E. coli* isolates, and 408 going by past reported findings this *blaox*_A genotype is associated with wide range of difficult-to-treat 409 infections owing to their hydrolyzing activity towards a variety of antibiotics (32). This therefore may have 410 influenced the revealed findings where most of the E. coli obtained isolates expressed drug and multidrug 411 resistance trends towards test antibiotics that are commonly used in the Kenyan health facilities to treat UTI. 412 This included resistance towards ceftazidime, cefepime, nitrofurantoin and much more against ampicillin at 413 a range between 60-75% (33). However, the occurrence of strains that did express co-carriage of resistance 414 genes still raises lots of health concerns more so if they are implicated in infections, since there will be very 415 minimal available treatment options. 416

The carriage of *bla_{CTX-M}* EβSL genotype among uropathogens have been recorded to have led to major health challenges in the treatment of community acquired UTIs (4), this study however differs a lot with the others studies since the presence of carriage *bla_{CTX-M}* EβSL genotype was not detected. The *bla_{CTX-M}* genes have been documented as the most commonly known ESβLs genotype obtained among uropathogens that is easily acquired via horizontal gene transfer (29)(34). In addition, these *bla_{CTX-M}* genes are known to be of significant medical challenge as they enable bacterial pathogens to easily hydrolyze Cefotaxime one of the many commonly used antibiotic to treat UTIs (29). Even so, the luck of *bla_{CTX-M}* isolation in the study

demonstrates there might be a new dynamic of the distribution of resistance genes among uropathogens and based on that our data, we advocate for routine screening of the carriage of EβSL genes to help inform and guide the periodic revision of UTI management. Furthermore, the obtained genotypic characterization finding of uropathogens will also be needed to obtain data that will aid in reducing the rate of spread and emergence of new resistance genes. Though the total cessation of emergence and spread of AMR genes still seems to be impossible, it's upon the health stakeholders to accelerate education campaigns on UTIs as a prophylactic measure to enlighten the society and assist halt UTI contraction.

This study phylogeny analysis showed significant similarity among the *E. coli* isolates at more than 70%. 431 The E. coli strains had the same identical resistance phenotypes and shared more than 75% genetic 432 similarity. Though previously documented finding reported a positive correlation between genetic diversity 433 and acquisition of antimicrobial resistance among bacteria uropathogens (35), this study finding is different 434 and varies with that of a previous study where E. coli isolates exhibited high rates of genetic change as well 435 as exhibition of high resistance rates against test antibiotics (34). However, the finding is of significant 436 clinical importance since it reveals how some strains of the same genetic similarity can possess drug and 437 multi-drug resistance genes. Close monitoring, and screening of genetic similarity among uropathogens is 438 therefore paramount to aid in management and halt spread of pathogens that have become more notorious to 439 treat by a range of clinically known antimicrobial agents (35). 440

In addition, the formation of biofilms by pathogenic bacteria and the contribution of these biofilms to AMR 441 is also another situation that is complex and causes a significant health dilemma. For example, the gains and 442 losses of resistance genes and the ability to form biofilms by bacteria especially those causing urinary tract 443 infection need to be known to shed light on more crucial knowledge of the dynamics that occur within the 444 said biofilms. According to the past documented findings, positive correlation between biofilm-related genes 445 and antibiotic resistance genes is a largely notable impact that affects the static/cidal actions of antibiotics 446 (10),(12),(36). Microbes inside these said biofilms are protected from attack by the host immune system or 447 even the administered antibiotics leading to disease establishment and enhanced treatment failure (10), (12), 448 (36). From this study majority of the isolates had the ability to form biofilm- at 63.2% and although our data 449

analysis showed no significant difference in biofilm formation among all tested isolates with the p-values 450 being more than 0.05, it is worth noting that overall, the Gram-positive isolates had significant P-value of 451 452 0.0561 Table 3.1. Gram-negative isolates were the most prevalent in forming biofilms at 69.5% (25/36) compared to the Gram-positive 30.5% (11/36). An observation that may be afflicted to the high resistance 453 profiles finding shown by Gram-negative isolates against test drugs; Ampicillin, Cefotaxime, Cefepime and 454 Ciprofloxacin at range of more than 40 % (18). Further analysis based on our comparative biofilm formation 455 between Gram-negatives and Gram-positives isolates, revealed E. coli isolates still as the most prevalent 456 biofilm formers at 41.7 % (14). The biofilm reduces the microbes' susceptibility to antibiotics due to the 457 biofilm exopolysaccharide polymers formed by the mass of bacterial cells that houses them. This allows the 458 microbes more time to keep on multiplying and producing more virulence traits. The biofilm ability 459 observation seen among this study E. coli isolates coupled with the carriage of blatem, blashy and blaoxA 460 EBSL genotypes underpins the exemplary high antimicrobial and multidrug resistance trends revealed 461 among the Escherichia coli isolates towards Sulfamethoxazole, Nalidixic acid and Ampicillin of 64%, 50% 462 and 27% respectively (18). This may be a revelation as to why E. coli in particular is becoming more lethal 463 and more difficult pathogen to treat. The finding is in agreement with a related study that termed E. coli, S. 464 aureus and P. aeruginosa as the most notorious biofilm formers isolated from hospital and community-465 based infections (8). The other Gram-negative biofilm formers from the current study included Klebsiella 466 and Proteus isolates at 19.4% (6) and 8.3% (9) respectively. 467

For the Gram-positive study isolates, S. aureus isolates was the most prevalent biofilm formers at 19.4% (6), 468 followed by S. saprophyticus at 11.1% (10). The overall findings on biofilm formation ability by both 469 Gram-negatives and Gram-positives isolates therefore revealed a logical explanation that most uropathogens 470 are able form biofilms, that in return enable them to easily proliferate in the urinary tract since the biofilm 471 protect them from the acidic environment and the potent effects of the host immune responses and other 472 antimicrobials. Additionally, these biofilms allow easy transfer of resistance genes by the cells that are 473 closely placed and eventually may be playing an important role of facilitating plasmid horizontal gene 474 exchange between closely positioned microbes and enhancing the spread of resistance genes (37). 475

Our biofilm formation analysis based on gender also revealed isolates obtained from women samples being more of biofilm formers at 62.9% (35) compared to men at 5.6% (4). This finding is of significant importance and could be attributed to several factors like women's anatomy and indwelling intrauterine contraceptive device that partly enhances the establishment of biofilms by being instrumentation harbour or act as reservoirs of uropathogens. These provide anchorage support for microbial biofilm formation and also hinder easy flushing out of the attached uropathogens by urine (35); however, more research should be done to ascertain this assumption.

In the current study, the ability of test drugs to inhibit biofilm formation activity was also analyzed. This was 483 done using selected eight bacterial isolates: E. coli 3323, E. coli 5810, Klebsiella spp 3306, Klebsiella spp 484 3063, Staphylococcus spp 3309, Staphylococcus spp 3328, Proteus spp 3346, and Proteus spp 3268 based 485 on their antimicrobial resistance trends in our previous study (18). The antibiofilm formation activity 486 revealed significant findings of antibiofilm inhibitory effects across the different antibiotic's dosages; 487 Ampicillin, Ceftriaxone, Ciprofloxacin and Sulfamethoxazole Figure; 3.5.1; 3.5.2; 3.5.3 and 3.5.4. These 488 results are in tandem with those from a past study (27) and are still in agreement to the antimicrobial 489 susceptibility profiles in our previously conducted study (18). We can therefore anticipate that use of this 490 drugs as a prophylactic measure against uropathogens may be a future solution to counter uropathogens 491 microbial biofilm formation and eventually halt spread of resistance genes that have largely led to the rising 492 AMR. However, this suggestion needs a feasibility study to be fully validated. 493

Further antibiofilm inhibitory activity analysis revealed that test treatment drugs; Ampicillin, Ciprofloxacin 494 and Ceftriaxone dosages yielded the most significant antibiofilm inhibitory effects against the screened 495 isolates recording p values above 0.05 (*). On the other hand, Sulfamethoxazole had the least antibiofilm 496 inhibitory effects, an observation that concurs with the observed antimicrobial susceptibility test result 497 where most the isolates exhibited high resistance trends against Sulfamethoxazole at a range between 40% 498 and 80% (18). Ceftriaxone had the highest antibiofilm inhibitory effects which may be afflicted to the drugs 499 mode of action since it inhibits the mucopeptide synthesis of bacteria cell wall thus preventing bacteria cell 500 wall and cell division (10). However, Sulfamethoxazole mode of action is different as it involves inhibition 501

of dihydropteroate synthesis enzyme to prevent for bacterial synthesis of purines and DNA. This mode of 502 action cannot prevent the initial bacteria growth hence affords the bacteria ample time to form biofilms (28). 503 504 Even though understanding how antibiotics may inhibit biofilm formation is crucial, it should also be seen starting point to understanding the interplay between biofilm formation and the AMR. Health stake holders 505 should therefore fund more health campaign rallies and give out handouts on biofilm education to enlighten 506 the public domain on the ease of spread and acquisition of antimicrobial resistance genes within biofilms. 507 This will increase the limited knowledge in the society and enlighten people on how easily resistance genes 508 are transferred specifically those attributed to plasmid-borne integrons that is able to assemble genes in 509 cassettes resulting to compromised disease treatment (15)(38). 510

Further analysis based on the antibiofilm inhibitory effects demonstrated that in most of the test antibiotics. 511 less inhibitory effects were seen at high dosages as compared to lower ones. This is not an abnormal finding 512 as it has been documented that at high dosages sometimes aggregation can occur of the drug at the point of 513 entry unto the bacteria cell and hence not much of the drug enters the target site. This for instance, was 514 documented by Omwenga et al., (27), when they were working with nanoencapsulated flavonoids against 515 quorum sensing and Awour et al., (39) when they were working with antibiofilm formation of V. cholerae 516 isolates against selected antibiotics. Nevertheless, several solutions have been identified to counteract 517 518 biofilms formation such as rifampicin for Gram-positive bacteria and fluoroquinolones for Gram-negative bacteria (40), the available anti-biofilms options are however still limited and leave a huge health concern 519 gap. More options are needed to increase the available choices and intensify the fight against antimicrobial 520 resistance trends since most of the antibiofilm compounds are not bacteria cidal and only render the cells in 521 a planktonic growth state, which are more susceptible to antibiotics and more easily cleared by the immune 522 system (20). Scientists should lobby and embrace more biofilm research work to open up more channels for 523 exploring new anti-biofilm formation inhibitory strategies and curb the contribution of biofilms in microbial 524 survival, persistence and encouragement antibiotic resistance. 525

526

528 5.0 Conclusion

According to the current study, the ultimate goal to achieve amicable antimicrobial stewardship and curb the rising treatment failure of urinary tract infection could be via a holistic campaign of mapping the carriage of resistance genes and biofilm formation. This will help revise the existing empiric treatment regimens now informed by the data of the prevailing resistance phenotypes. Besides, the data will assist in preserving the potency of β -lactam antibiotics and improve success of chemotherapy. The public domain will again be reassured the of a health solution, since there is limited hope of new novel drugs.

However, this study was only able to screen a few selected ESBLs genes and the possibility of biofilm formation among the screened bacteria etiological agents. Future studies that will focus more on detection of other AMR genes against other class antibiotics and biofilm genes are encouraged. The development of novel antibiotics, biofilm formation inhibitory compounds and vaccines against bacteria causing urinary tract infections will also be a milestone achievement for the modern medicine.

540 6.0 Study Limitations

541 This study had a number of shortcomings that can be addressed in future surveillance studies;

- We were only able to for a few EβSLs genotypes. Future studies to determine the carriage of other β lactamase genes are fundamental. We were also not able to screen the carriage of other classes of
 resistance genes that are associated to resistance to other classes of antimicrobial agents like
 fluoroquinolones and aminoglycosides.
- We were only able to determine the possibility of biofilm formation among the screened isolates.
 However, future studies can therefore involve the screening of carriage of genes associated with
 biofilms to shed lighter on bacterial host invasion and pathogenesis.

549 Acknowledgements

550 To the study participants, thank you for agreeing to take part in this study. The authors wish to further 551 express heartfelt gratitude to all KEMRI/CMR (molecular biology) staff members particularly Susan

- 552 Wambui Kiiru for their invaluable support. We are also grateful to the clinicians, laboratory technologists,
- and the administration Kiambu level 5 Hospital for their guidance and assistance. This study was funded by
- 554 HATUA (Holistic Approach to Unravel Antimicrobial resistance in East Africa) research funds. The funders
- had no role in study design, data collection and analysis, decision to publish, or manuscript preparation.

556 Conflict of Interests

557 There is no conflict of interests.

558 Author's Contribution

Fredrick Wanja (FW) was the principal investigator and came up with the study concept. FW designed, carried out the lab work, data analysis and drafted the manuscript. John Maina participated in sample collection, lab work and drafting of the manuscript. Dr. Caroline Ngugi and Dr. Eric Omwenga assisted in preparation and harmonization of the manuscript. Dr. John Kiiru took part in the study design and supervised the lab bench work. All authors read and endorsed the manuscript.

564 Author's Information

Fredrick Kimunya (FK) is a master's student in Kenya studying Infectious Diseases and Vaccinology at 565 Jomo Kenyatta University of agriculture and technology. John Maina (JM) is a scientific researcher at the 566 Centre of Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya. Dr. Caroline Ngugi 567 (CN) is the Chairperson Department of Medical Microbiology, Jomo Kenyatta University of agriculture and 568 technology who possess vast experience in proposal development. Dr. Eric Omwenga (EO) is the 569 Chairperson Department of Microbiology & Parasitological, Kisii University. He assisted in coming up with 570 571 the study concept and revision of the content of the manuscript. Dr. John Kiiru (JK) a senior researcher at the Centre of Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya and the Head of 572 Laboratory Ministry of Health, Nairobi, Kenya who have vast knowledge in infectious diseases and 573 microbiology took part in the study design and actualization of the content of the manuscript. 574

Ethical Approval

577	Approved	(Supplementary	v data S 1	and Suppl	ementary	data S 2)
577	rippioved	(Suppremental)	y uata D I	and Suppi	cincinal y	uata $D \mathcal{L}_{j}$,

perpetuity. It is made available under a CC-BY 4.0 International license

591 **REFERENCES**

- 592 1. V. M. Lema. Urinary Tract Infection In Young Healthy Women Following Heterosexual Anal
- 593 Intercourse: Case Reports | Lema | African Journal of Reproductive Health [Internet]. African journal
- of reproductive health. 2015 [cited 2022 Sep 26]. Available from:
- 595 https://www.ajrh.info/index.php/ajrh/article/view/844
- 596 2. Saha S, Rahman S, Hassan FMN, Sarkar S, Islam K, Saha P, et al. Antimicrobial Resistance in
- 597 Uropathogen Isolates from Patients with Urinary Tract Infections. Biomedical Research and Therapy
- 598 2015 2:5 [Internet]. 2015 May 28 [cited 2022 Sep 27];2(5):1–7. Available from:
- 599 https://link.springer.com/article/10.7603/s40730-015-0011-3
- 600 3. Lim YK, Lee MK, Kim TH. Management of Extended-Spectrum Beta-Lactamase-Positive Gram-
- 601 Negative Bacterial Urologic Infections. undefined. 2015;10(2):84.
- 4. Kiiru J, Kariuki S, Goddeeris BM, Butaye P. Analysis of β-lactamase phenotypes and carriage of
- β selected β-lactamase genes among Escherichia coli strains obtained from Kenyan patients during an
- 18-year period. BMC Microbiol [Internet]. 2012 [cited 2022 Sep 27];12. Available from:
- 605 https://pubmed.ncbi.nlm.nih.gov/22838634/
- 5. Gundran RS, Cardenio PA, Villanueva MA, Sison FB, Benigno CC, Kreausukon K, et al. Prevalence
- and distribution of bla CTX-M, bla SHV, bla TEM genes in extended- spectrum β Lactamase-
- producing E. coli isolates from broiler farms in the Philippines. BMC Vet Res [Internet]. 2019 Jul 5
- 609 [cited 2022 Sep 27];15(1):1–8. Available from:
- https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-019-1975-9
- 6. Kargar M, Jahromi MZ, Najafi A, Ghorbani-Dalini S, Kargar M. Molecular detection of ESBLs
- 612 production and antibiotic resistance patterns in Gram negative bacilli isolated from urinary tract
- 613 infections. Indian J Pathol Microbiol [Internet]. 2014 [cited 2022 Sep 27];57(2):244. Available from:
- 614 https://www.ijpmonline.org/article.asp?issn=0377-
- 4929;year=2014;volume=57;issue=2;spage=244;epage=248;aulast=Kargar

- 616 7. Wilmore SMS, Kranzer K, Williams A, Makamure B, Nhidza AF, Mayini J, et al. Carriage of
- 617 extended-spectrum beta-lactamase-producing Enterobacteriaceae in HIV-infected children in
- 218 Zimbabwe. J Med Microbiol [Internet]. 2017 May 1 [cited 2022 Sep 27];66(5):609–15. Available
- from: https://pubmed.ncbi.nlm.nih.gov/28513417/
- 8. Kalita A, Hu J, Torres AG. Recent advances in adherence and invasion of pathogenic Escherichia
- coli. Curr Opin Infect Dis [Internet]. 2014 [cited 2022 Sep 27];27(5):459–64. Available from:
- 622 https://pubmed.ncbi.nlm.nih.gov/25023740/
- Sauer K. The genomics and proteomics of biofilm formation. Genome Biol [Internet]. 2003 May 27
 [cited 2022 Sep 27];4(6):1–5. Available from:
- https://genomebiology.biomedcentral.com/articles/10.1186/gb-2003-4-6-219
- 10. Chen M, Yu Q, Sun H. Novel Strategies for the Prevention and Treatment of Biofilm Related
- 627 Infections. Int J Mol Sci [Internet]. 2013 Sep 6 [cited 2022 Sep 27];14(9):18488. Available from:
 628 /pmc/articles/PMC3794791/
- Donlan RM. Biofilms: microbial life on surfaces. Emerg Infect Dis [Internet]. 2002 [cited 2022 Sep
 27];8(9):881–90. Available from: https://pubmed.ncbi.nlm.nih.gov/12194761/
- Choong S, Whitfield H. Biofilms and their role in infections in urology. BJU Int [Internet]. 2000
 [cited 2022 Sep 27];86(8):935–41. Available from: https://pubmed.ncbi.nlm.nih.gov/11069430/
- 13. Reiter KC, da Silva Paim TG, de Oliveira CF, D'Azevedo PA. High biofilm production by invasive
- multiresistant staphylococci. APMIS [Internet]. 2011 Nov [cited 2022 Sep 27];119(11):776–81.
- 635 Available from: https://pubmed.ncbi.nlm.nih.gov/21995631/
- 14. Soto SM, Smithson A, Martinez JA, Horcajada JP, Mensa J, Vila J. Biofilm Formation in
- 637 Uropathogenic Escherichia coli Strains: Relationship With Prostatitis, Urovirulence Factors and
- Antimicrobial Resistance. J Urol [Internet]. 2007 Jan [cited 2022 Sep 27];177(1):365–8. Available
- from: https://www.auajournals.org/doi/10.1016/j.juro.2006.08.081

- 15. Cepas V, López Y, Muñoz E, Rolo D, Ardanuy C, Martí S, et al. Relationship Between Biofilm
- 641 Formation and Antimicrobial Resistance in Gram-Negative Bacteria. Microb Drug Resist [Internet].
- 642 2019 Jan 1 [cited 2022 Sep 27];25(1):72–9. Available from:
- 643 https://pubmed.ncbi.nlm.nih.gov/30142035/
- 16. Huynh BT, Passet V, Rakotondrasoa A, Diallo T, Kerleguer A, Hennart M, et al. Klebsiella
- 645 pneumoniae carriage in low-income countries: antimicrobial resistance, genomic diversity and risk
- factors. Gut Microbes [Internet]. 2020 Sep 2 [cited 2022 Sep 27];11(5):1287–99. Available from:
- 647 https://pubmed.ncbi.nlm.nih.gov/32404021/
- 17. Zhang L, Mah TF. Involvement of a Novel Efflux System in Biofilm-Specific Resistance to
- Antibiotics. J Bacteriol [Internet]. 2008 Jul [cited 2022 Sep 27];190(13):4447. Available from:
- 650 /pmc/articles/PMC2446775/
- 18. Wanja F, Ngugi C, Omwenga E, Maina J, Kiiru J, Wanja F, et al. Urinary Tract Infection among
- Adults Seeking Medicare at Kiambu Level 5 Hospital, Kenya: Prevalence, Diversity, Antimicrobial
- 653 Susceptibility Profiles and Possible Risk Factors. Adv Microbiol [Internet]. 2021 Jul 29 [cited 2022
- 654 Sep 27];11(8):360–83. Available from:
- http://www.scirp.org/journal/PaperInformation.aspx?PaperID=111014
- 19. Kinnari TJ. The role of biofilm in chronic laryngitis and in head and neck cancer. Curr Opin
- Otolaryngol Head Neck Surg [Internet]. 2015 [cited 2022 Sep 27];23(6):448–53. Available from:
 https://pubmed.ncbi.nlm.nih.gov/26371604/
- Bernardes E van T, Lewenza S, Reckseidler-Zenteno S. Current Research Approaches to Target
 Biofilm Infections. Postdoc J [Internet]. 2015 Jun 18 [cited 2022 Sep 27];3(6). Available from:
 https://pubmed.ncbi.nlm.nih.gov/28748199/
- 662 21. de Oliveira CF, Paim TG da S, Reiter KC, Rieger A, D'Azevedo PA. Evaluation of four different
- 663 DNA extraction methods in coagulase-negative staphylococci clinical isolates. Rev Inst Med Trop

- 664 Sao Paulo [Internet]. 2014 Jan [cited 2022 Sep 27];56(1):29–33. Available from:
- 665 https://pubmed.ncbi.nlm.nih.gov/24553605/
- 666 22. Gootz TD, Lescoe MK, Dib-Hajj F, Dougherty BA, He W, Della-Latta P, et al. Genetic organization
- of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains
- isolated in a New York City hospital. Antimicrob Agents Chemother [Internet]. 2009 May [cited 2022]
- 669 Sep 27];53(5):1998–2004. Available from: https://pubmed.ncbi.nlm.nih.gov/19258268/
- 670 23. Hasman H, Mevius D, Veldman K, Olesen I, Aarestrup FM. beta-Lactamases among extended-
- 671 spectrum beta-lactamase (ESBL)-resistant Salmonella from poultry, poultry products and human
- patients in The Netherlands. J Antimicrob Chemother [Internet]. 2005 Jul [cited 2022 Sep
- 673 27];56(1):115–21. Available from: https://pubmed.ncbi.nlm.nih.gov/15941775/
- 674 24. Ibrahim DR, Dodd CER, Stekel DJ, Ramsden SJ, Hobman JL. Multidrug resistant, extended spectrum
- 675 β-lactamase (ESBL)-producing Escherichia coli isolated from a dairy farm. FEMS Microbiol Ecol
- 676 [Internet]. 2016 Apr 1 [cited 2022 Sep 27];92(4). Available from:
- 677 https://academic.oup.com/femsec/article/92/4/fiw013/2197676
- M. MOGHOOFEI HFFP and EN. Effects of environmental conditions on the morphologic change of
 ...: Ingenta Connect [Internet]. 2015 [cited 2022 Sep 27]. Available from:
- https://www.ingentaconnect.com/content/doaj/23225173/2015/0000004/00000015/art00003?crawler
 =true
- Kadurugamuwa JL, Sin L, Albert E, Yu J, Francis K, DeBoer M, et al. Direct continuous method for
 monitoring biofilm infection in a mouse model. Infect Immun. 2003 Feb 1;71(2):882–90.
- 684 27. Omwenga EO, Hensel A, Pereira S, Shitandi AA, Goycoolea FM. Antiquorum sensing, antibiofilm
- formation and cytotoxicity activity of commonly used medicinal plants by inhabitants of Borabu sub-
- 686 county, Nyamira County, Kenya. PLoS One [Internet]. 2017 Nov 1 [cited 2022 Sep 27];12(11).
- 687 Available from: https://pubmed.ncbi.nlm.nih.gov/29091715/

- 28. Sharma M, Pathak S, Srivastava P. Prevalence and antibiogram of Extended Spectrum β-Lactamase 688
- (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producing 689
- Escherichia coli and Klebsiella spp. J Clin Diagn Res [Internet]. 2013 Oct 5 [cited 2022 Sep 690
- 27];7(10):2173-7. Available from: https://pubmed.ncbi.nlm.nih.gov/24298468/ 691
- Bowler P, Murphy C, Wolcott R. Biofilm exacerbates antibiotic resistance: Is this a current oversight 29. 692
- in antimicrobial stewardship? Antimicrob Resist Infect Control [Internet]. 2020 Dec 1 [cited 2022 Sep 693
- 27]:9(1). Available from: https://pubmed.ncbi.nlm.nih.gov/33081846/ 694
- Abrar S, Ain NU, Liagat H, Hussain S, Rasheed F, Riaz S. Distribution of bla CTX-M, bla TEM, bla 30. 695
- SHV and bla OXA genes in Extended-spectrum-β-lactamase-producing Clinical isolates: A three-year 696
- multi-center study from Lahore, Pakistan. Antimicrob Resist Infect Control [Internet]. 2019 May 22 697
- [cited 2022 Sep 27];8(1):1–10. Available from: 698
- https://aricjournal.biomedcentral.com/articles/10.1186/s13756-019-0536-0 699
- Liakopoulos A, Mevius D, Ceccarelli D. A review of SHV extended-spectrum β-lactamases: 700 31. Neglected yet ubiquitous. Front Microbiol. 2016 Sep 5;7(SEP):1374.
- 701
- 32. C. Hou and F. Yang. Drug-resistant gene of blaOXA-23, blaOXA-24, blaOXA-51 and blaOXA-58 in 702
- Acinetobacter baumannii PubMed [Internet]. 2015 [cited 2022 Sep 27]. Available from: 703
- https://pubmed.ncbi.nlm.nih.gov/26550338/ 704
- Durante-Mangoni E, Zarrilli R. Global spread of drug-resistant Acinetobacter baumannii: molecular 33. 705 epidemiology and management of antimicrobial resistance. Future Microbiol [Internet]. 2011 Apr 706
- [cited 2022 Sep 27];6(4):407–22. Available from: https://pubmed.ncbi.nlm.nih.gov/21526942/ 707
- Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new β-34. 708
- 709 lactamases from gram-negative bacteria. Annu Rev Microbiol [Internet]. 2011 [cited 2022 Sep
- 27];65:455–78. Available from: https://pubmed.ncbi.nlm.nih.gov/21740228/ 710
- Touchon M, Hoede C, Tenaillon O, Barbe V, Baeriswyl S, Bidet P, et al. Organised genome 35. 711
- 712 dynamics in the Escherichia coli species results in highly diverse adaptive paths. PLoS Genet

		medRxiv preprint doi: https://doi.org/10.1101/2022.10.23.22281223; this version posted October 25, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
713		[Internet]. 2009 [cited 2022 Sep 27];5(1). Available from:
714		https://pubmed.ncbi.nlm.nih.gov/19165319/
715	36.	Yousefi M, Pourmand MR, Fallah F, Hashemi A, Mashhadi R, Nazari-Alam A. Characterization of
716		Staphylococcus aureus Biofilm Formation in Urinary Tract Infection. Iran J Public Health [Internet].
717		2016 Apr 27 [cited 2022 Sep 27];45(4):485. Available from: /pmc/articles/PMC4888176/
718	37.	Watnick P, Kolter R. Biofilm, city of microbes. J Bacteriol [Internet]. 2000 May [cited 2022 Sep
719		27];182(10):2675–9. Available from: https://pubmed.ncbi.nlm.nih.gov/10781532/
720	38.	P. A. White CJM and WDR. White, P.A., McIver, C.J. and Rawlinson, W.D. (2001) Integrons and
721		Gene Cassettes in the Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 45, 2658-2661
722		References - Scientific Research Publishing [Internet]. 2001 [cited 2022 Sep 27]. Available from:
723		https://www.scirp.org/%28S%28351jmbntvnsjt1aadkposzje%29%29/reference/referencespapers.aspx
724		?referenceid=2526317
725	39.	Awuor SO, Omwenga EO, Mariita RM, Daud II. Cholera outbreak: antibiofilm activity, profiling of
726		antibiotic-resistant genes and virulence factors of toxigenic Vibrio cholerae isolates reveals
727		concerning traits. Access Microbiol [Internet]. 2022 Mar 23 [cited 2022 Sep 27];4(3). Available from:
728		https://pubmed.ncbi.nlm.nih.gov/35693465/
729	40.	Kinnari TJ. The role of biofilm in chronic laryngitis and in head and neck cancer. Curr Opin
730		Otolaryngol Head Neck Surg [Internet]. 2015 [cited 2022 Sep 27];23(6):448-53. Available from:
731		https://pubmed.ncbi.nlm.nih.gov/26371604/
732		
733		

Supplementary Data S1 737

Research consent form 738

- Title: Genotypic Characterization of Urinary Tract Infections causing bacteria isolates among Adults 739
- at Kiambu Level 5 Hospital, Kenya: Selected Extended Spectrum *β*-Lactamase genes and Biofilm 740
- Formation 741

Purpose of the research study? 742

Dear participant you are requested to take part in this study. The study aims to obtain information about the 743 genotypic characterization and biofilm formation of isolated uropathogens among adult patients attending 744 Kiambu level 5 hospital. Kindly read through the following information and also listen as I explain to you 745 all that the study entails. In case of any words, terms, or sections that are not clearly understood, you are 746 747 highly encouraged to seek further explanation. Ask any question about the study that you feel it concerns you. If you accept to take part in the study, please fill in this form and keep your copy for personal records. 748 The form has important information about the names and physical address which you can use in the future to 749 make any inquiries about the study. 750

You are invited to consent or decline to consent to do the following: 751

- 1. Provide a urine sample 752
- 2. Allow us to keep the urine specimen obtained from you by freezing or any other means of long term 753 preservation. 754
- 3. Allow storage and use of bacterial isolate strains from this study for future studies related to UTI 755 investigations or further analysis. 756

I would also like to disclose to you the following information involving the study: 757

Some of the questions you are about to be asked may be uncomfortable or personally, however, you 758 are assured that optimum privacy and confidentiality before consenting, during and post the study 759 exercises will be observed. 760

- Data collected will only be accessed by the study relevant authorities and only used for the purposes of this study.
- You may find it a bit challenging or embarrassing to collect urine sample but I will explain to you
 the best and most comfortable manner to do so.
- The main purpose of obtaining a urine sample from you is to determine whether you have developed
 a UTI or not. Isolated uropathogens will further be subjected to antimicrobial susceptibility test to
 determine appropriate drug of choice. Genetic relatedness of the isolates will also be determined to
 make good informed study conclusions.
- There are no incentives or monetary gains for participating in this study.
- Participation in this study is on a voluntary basis and one can decline to continue to answer or
 participate if you feel like.
- One can also withdraw from the study any time you feel like and this will not draw any penalties or
 discrimination in the future.
- My role as the principal investigator is to provide all the information about the study and the findings
 data to the clinicians at Kiambu level 5 hospital to aid in treating you. However, you will be required
 to cater for bills that will arise from your sickness like purchasing the prescribed antibiotics.

777 Your role as the participant in this research study.

You will be required to provide a urine sample that will be used for investigation of UTI causing bacteria. For the purpose of the study, you are also required to consent on your behalf, after which you will now obtain a urine sample. The urine sample will not be stored after culture is performed but disposed according to KEMRI biosafety procedures immediately. Please note that the isolated biological samples may be used for future studies and you are therefore requested to consent to allow their use as and when required.

783 Additional procedure for patients who will participate in this study

For urine samples taken and found to be positive of UTI, the participant results will be shared with the clinicians who will then treat you. Sample collection will be on sterile universal container and you will be

given instructions on how to best collect and pack the clean catch mid- stream urine sample. You will collect
the urine sample within the hospital compound and provide it to the lab immediately. Only samples provided

to the lab within two hours will be accepted.

789 What will happen after the study?

Data obtained from this study will be used to determine the various bacterial species prevalence, antimicrobial susceptibility profiles, biofilm formation ability and carriage of ESBLs genes by the isolated bacterial uropathogens among adult patients attending Kiambu level 5 hospital. This data will also provide critical information that will enhance the diagnosis of these infections in the facility and aid in treatment of participants found to be positive of UTI. The data will help to enlighten the facility administration if there is need to revise and improve policies on how to manage UTI among patients visiting the facility. This is in regard to conducting routine urine culture and prescription of antibiotics.

797 What happens in case the participant has a change of mind?

If you had agreed to take part in the study and with time you happen to change your mind, you are free to withdraw at any time with no penalties. You will also not be discriminated in any way in the future due to your decision to withdraw.

801 Who will read or hear about information collected from the participant.

The information collected from the participant will be stored using the assigned study number/ code since no name will be indicated. The coded information will also be stored in soft copy format on computers protected by passwords only known by the study relevant authorities.

Do you have any questions about the study that you feel was left out, was not addressed or was not well understood?

- Feel free to ask and I will answer you now. If you would like to inquire more details about the research
- study or have any issues about your rights to participate that need to be discussed in the future, you can
- so contact any of the following people;
- 1. The Secretary, KNH-UoN Ethics and Research Committee. College of Health Sciences P.O Box
- 811 **19676-00202, Nairobi Tel. (254-0200) 2726300-9 Ext 44355.**
- 812 2. Fredrick Kimunya Wanja (Principal Investigator) +254724089245.
- 813 3. Dr. John N Kiiru, CMR- KEMRI +254721805285
- 4. Dr. Caroline Ngugi, Dept. of Medical Microbiology, JKUAT +254722556790
- 5. Dr. Eric Omwenga, Dept. of Bio &Nanotechnology, Kisii University- +254725806875
- 816 Laboratory number.....
- 817 **Telephone number**.....
- I have read the above information to the best of my knowledge and have had the opportunity to ask questions which were all answered to my satisfactory. I consent to participate in the study as has been explained and as I have understood it.
- 821 Signature
- 822 **Date**
- 823
- 824 Right or Left hand thumb print for those who cannot sign
- 825

826 Name of principle investigator.....

- 827
- 828 Signature..... Date.....